Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Long-term Pain Modulation by Intravenous Esketamine in Complex Regional Pain Syndrome: a Non-inferiority Study

To see complete record on, please visit this link

Id: NCT05212571

Organisation Name: Erasmus Medical Center

Overal Status: Recruiting

Start Date: April 19, 2022

Last Update: May 20, 2022

Lead Sponsor: Erasmus Medical Center

Brief Summary: Intravenous administration of esketamine is an effective recognized therapeutic option in refractory pain in CRPS, which sometimes in at least a part of the patients has a prolonged therapeutic effect. Unfortunately, CRPS literature contains a wide range of ketamine dosing regimens with the result that clinical protocols on dosage and administration are very heterogeneous. The current esketamine regimen in Erasmus MC consists of a 6-day hospital admission for continuous administration. In the Netherlands, both inpatient and outpatient esketamine treatments are offered. Inpatient and outpatient ketamine treatments have never been compared in randomized controlled trials and it is therefore unknown whether these two dosing regimens are equally effective.

The primary objective is to demonstrate non-inferiority of experimental esketamine administration of 6x 1 day per 2 weeks (in total 3 months) as compared with standard esketamine administration of 1x 6 consecutive days. The end of study is at 6 months after the start of the study/treatment.

  • Complex Regional Pain Syndromes
  • CRPS (Complex Regional Pain Syndromes)

Total execution time in seconds: 0.19448113441467